Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has received an average rating of "Moderate Buy" from the eight analysts that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $13.17.
Several brokerages have recently commented on ALLO. JPMorgan Chase & Co. lowered their target price on shares of Allogene Therapeutics from $9.00 to $8.00 and set an "overweight" rating on the stock in a report on Tuesday, February 27th. Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 target price on shares of Allogene Therapeutics in a research report on Friday, March 15th. JMP Securities reissued a "market perform" rating on shares of Allogene Therapeutics in a research note on Friday, January 5th. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Allogene Therapeutics in a research report on Tuesday, March 19th. Finally, Guggenheim downgraded Allogene Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, January 5th.
Check Out Our Latest Stock Report on ALLO
Institutional Trading of Allogene Therapeutics
Several hedge funds have recently bought and sold shares of ALLO. FMR LLC boosted its stake in Allogene Therapeutics by 0.9% during the 3rd quarter. FMR LLC now owns 25,143,931 shares of the company's stock valued at $79,706,000 after purchasing an additional 225,976 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Allogene Therapeutics by 41.1% during the third quarter. Vanguard Group Inc. now owns 10,587,804 shares of the company's stock valued at $33,563,000 after buying an additional 3,086,311 shares during the last quarter. BlackRock Inc. grew its holdings in Allogene Therapeutics by 2.7% during the first quarter. BlackRock Inc. now owns 9,123,092 shares of the company's stock worth $45,068,000 after buying an additional 236,520 shares in the last quarter. State Street Corp raised its position in Allogene Therapeutics by 3.3% in the 2nd quarter. State Street Corp now owns 8,478,761 shares of the company's stock valued at $42,139,000 after buying an additional 267,687 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Allogene Therapeutics by 12.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 6,910,882 shares of the company's stock valued at $21,907,000 after buying an additional 776,487 shares during the last quarter. Institutional investors and hedge funds own 83.63% of the company's stock.
Allogene Therapeutics Price Performance
NASDAQ ALLO traded down $0.19 on Friday, hitting $3.80. 2,882,299 shares of the stock were exchanged, compared to its average volume of 2,635,534. The business's fifty day moving average is $4.57 and its 200 day moving average is $3.53. Allogene Therapeutics has a 52 week low of $2.23 and a 52 week high of $6.89. The company has a market capitalization of $642.54 million, a PE ratio of -1.82 and a beta of 0.81.
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.04. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.05 million. Allogene Therapeutics had a negative return on equity of 53.76% and a negative net margin of 202,366.25%. Analysts predict that Allogene Therapeutics will post -1.69 EPS for the current fiscal year.
About Allogene Therapeutics
(
Get Free ReportAllogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
See Also
Before you consider Allogene Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.
While Allogene Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
